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6/j.bThe synthetic triterpenoid CDDO-Me has been shown to directly inhibit the growth of myeloid leukemias and
lends itself to a wide array of therapeutic indications, including inflammatory conditions, because of its inhibi-
tion of NF-kB. We have previously demonstrated protection from acute graft-versus-host disease after
CDDO-Me administration in an allogeneic bone marrow transplantation model. In the current study, we ob-
served that CDDO-Me promoted myelopoiesis in both naive and transplanted mice. This effect was dose de-
pendent, as high doses of CDDO-Me inhibited myeloid growth in vitro. All lineages (granulocyte macrophage
colony-forming unit, BFU-E) were promoted by CDDO-Me. We then compared the effects with granulocyte
colony-stimulating factor, a known inducer of myeloid expansion and mobilization from the bone marrow.
Whereas both drugs induced terminal myeloid expansion in the spleen, peripheral blood, and bone marrow,
granulocyte colony-stimulating factor only induced granulocytemacrophage colony-forming unit precursors in
the spleen, while CDDO-Me increased these precursors in the spleen and bonemarrow. After sublethal total-
body irradiation, mice pretreated with CDDO-Me further displayed an accelerated recovery of myeloid pro-
genitors and total nucleated cells in the spleen. A similar expansion of myeloid and myeloid progenitors was
notedwithCDDO-Me treatment after syngeneic bonemarrow transplantation. Combined, these data suggest
that CDDO-Me may be of use posttransplantation to accelerate myeloid recovery in addition to the preven-
tion of graft-versus-host disease.
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Hematopoietic stem cell transplantation (HSCT) is
frequently used in the treatment of various hematolog-
ical malignancies, immune deficiencies, and anemias.
The recovery period after HSCT is characterized by
prolonged neutropenia, thus increasing susceptibility
to opportunistic infections and related mortalities
[1,2]. Granulocyte colony-stimulating factor (G-CSF,
filgrastim) is used clinically to accelerate donormyeloid
recovery and to minimize the duration of neutropenia
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bmt.2011.11.013has been shown to decrease the time required for abso-
lute neutrophil counts to reach above 500/mL, a com-
monly examined clinical threshold, and is regularly
used in the clinic [3].
CDDO-Me (methyl-2-cyano-3, 12-dioxooleana-
1, 9-diene-28-oate; bardoxolone methyl) is a synthetic
triterpenoid that has been previously shown to induce
apoptosis and inhibit growth in a number of hemato-
logic and nonhematologic malignancies [4-7], as well
as to improve renal function in patients with chronic
kidney disease [8]. CDDO-Me induces the Keap1-
Nrf2 pathway, thereby upregulating many antioxidant
and cytoprotective genes [8,9]. CDDO-Me has been
shown to protect against oxidative stress caused by in-
ducible nitric oxide synthase. An elevation of NAD(P)
H-quinone oxidoreductase and heme oxygenase, both
of which protect cells from redox cycling and oxidative
stress, are believed to mediate the antioxidant proper-
ties of CDDO-Me [10]. However, growth and survival
inhibition have also been shown by CDDO-Me, most
likely mediated by the blockade of NF-kB through the
inhibition of IlBa kinase-b (IKK-b) [11]. Based on the
antioxidant role of CDDO-Me, a recent study found
that CDDO-Me can inhibit the suppressive activity
of myeloid-derived suppressor cells, which utilize re-
active oxygen species as a mechanism of suppression
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sponses [12]. Studies in our laboratory have addition-
ally demonstrated that CDDO-Me inhibits the
severity and development of acute murine graft-
versus-host disease (GVHD) after allogeneic HSCT
in mice and was shown to induce cell death in prolifer-
ating lymphocytes in a mixed lymphocyte reaction
[13]. To our surprise in these studies, mice that re-
ceived CDDO-Me were not only protected from
GVHD but also displayed an expansion of myeloid
progenitor grabulocyte macrophage-colony forming
unit (GM-CFU) cells within the spleen and bone
marrow.
In the current study, we examined the effects of
CDDO-Me on hematopoiesis and compared adminis-
tration of CDDO-Me with G-CSF in terms of their
respective abilities to induce myelopoiesis and expand
myeloid cells in resting and syngeneic HSCT mice.
We found that both CDDO-Me andG-CSF expanded
CD11b1Gr-11myeloid cells in the bone marrow and
spleen. However, CDDO-Me administration also in-
creased the amount of GM-CFU and BFU-e colonies
in the spleen, bone marrow, and blood, while G-CSF
administration only increased GM-CFU and BFU-e
colonies in the spleen and blood. Additionally,
the number of GM-CFU and hematopoietic progeni-
tor cells (HPCs) in the spleen and bone marrow
showed a significant increase in mice that received
CDDO-Me. In vitro studies showed that CDDO-Me
was sufficient to stimulate colony growth of naive
bone marrow cells in suboptimal colony-stimulating
cytokine conditions. Given the broad effects of
CDDO-Me, the myeloid expansion we observed may
offer advantages in HSCT outcome.MATERIALS AND METHODS
Animals
Female C57BL/6 (B6) mice were obtained from
the Animal Production Area of the National Cancer
Institute (Frederick, MD). Mice were kept in specific
pathogen-free conditions at the University of Nevada,
Reno (Reno, NV) or at the University of California
Davis Medical Center (Sacramento, CA). All mice
were between 8 and 12 weeks of age at the start of
the experiments. Animal protocols were approved by
the Institutional Animal Care and Use Committees
at the respective institutions in which studies were
performed.Cells and Reagents
CDDO-Me was manufactured through the NIH
RAID Program and provided by Reata Pharmaceuti-
cals, Inc. (Irving, TX). CDDO-Me was prepared in
a vehicle solution of 10% dimethyl sulfoxide(DMSO) (Sigma, St. Louis, MO), 10% Cremophor
EL (Sigma), and 80% Dulbecco’s phosphate-
buffered saline (DPBS). A vehicle control consisting
of 10% DMSO, 10% Cremophor EL, and 80%
DPBS was used as a control in all experiments. G-
CSF (Neupogen, Amgen, Thousand Oaks, CA)
was diluted to the appropriate concentration in
DPBS. Except where indicated, mice received a treat-
ment schedule of CDDO-Me (120 mg/dose, twice
daily i.p.) or vehicle control for 7 days or G-CSF (2.5
mg/dose, twice daily s.q.) for 5 days. In naive mice,
a treatment schedule of 120 mg per injection for 7
days was chosen because it resulted in the greatest in-
crease in colony formation and was well tolerated.
Flow Cytometry
Single-cell suspensions (1  106) were prepared
from the spleen and bone marrow as described previ-
ously [14] and labeled with fluorochrome-conjugated
anti-mouse antibodies, and nonspecific binding was
corrected with isotype-matched controls. FITC anti-
CD11b (M1/70), PE-Cy5 anti-Gr-1 (RB6-8C5),
PE-Sca-1 (D7), FITC c-kit (2B8), and 7-AAD were
purchased from BD Biosciences (San Jose, CA).
Lineage-positive cells were excluded by simultaneous
staining with PE-Cy5-labeled anti-CD3ε, (145-
2C11), anti-Gr-1(RB6-8C5), anti- CD11b (M1/70),
anti-CD45R/B220 (RA3-6B2), and anti-(TER-119),
all purchased from BioLegend (San Diego, CA). Flow
cytometric acquisition was performed on a BD LSR
Fortessa (Becton Dickinson, San Jose, CA) or Strate-
digm S1400 (San Jose, CA). Data sets were analyzed
using FlowJo software (Tree Star, Ashland, OR).
Colony Assays
GM-CFU, BFU-e, and CFU-HPP colony assays
were performed as previously described [14,15]. For
GM-CFU and BFU-e assays, 5  104 bone marrow
cells or 5  105 splenocytes were plated in 35-mm
Petri dishes with methylcellulose-containing medium.
Colony formation was stimulated with 10 ng/mL re-
combinant murine granulocyte macrophage-colony
stimulating factor (GM-CSF), 10 ng/mL recombinant
murine interleukin (IL)-3, and 5 U/mL erythropoie-
tin. Plates were incubated 7 days at 37C at 5% CO2.
Colonies were defined as aggregates of 50 ormore cells
that contained only red cells (BFU-e) or only white
cells (GM-CFU). In assays with suboptimal cytokines,
colony growth was stimulated with 300 pg/mL
GM-CSF (without IL-3 or erythropoietin), and
CDDO-Me or vehicle control was added to dishes at
the indicated concentrations with the amount of vehi-
cle in each dish remaining constant. In CFU-HPP
assays, bone marrow cells or spleen cells were plated
in 60-mm Petri dishes at 5  104 or 5  105 cells per
plate, respectively. Colony formation was stimulated
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Figure 1. CDDO-Me stimulates GM-CFU formation at low concentra-
tions but is toxic at higher concentrations. Naivemouse splenocytes were
plated in a GM-CFU with a suboptimal amount of colony-stimulating
cytokines (0.3 ng/mL GM-CSF). CDDO-Me was added to Petri dishes
at the indicated concentrations while keeping the amount of vehicle in
each sample normalized. Plates were incubated for 7 days, at which
time colonies of .50 cells were counted. Colony counts from individual
experiments were normalized to the vehicle control in each experiment
and pooled. *P\.05 by Dunnett’s multiple comparison test.Total Body Irradiation and Bone Marrow
Transplantation
For radioprotection studies, mice received 120 mg
CDDO-Me on days 27 through 21 before sublethal
irradiation with 500 cGy from a 137Cs irradiator on
day 0. Mice were harvested on day 8 to determine ra-
dioprotection through CFU assays and total cell
counts through flow cytometry. For bone marrow
transplantation (BMT) studies. C57BL/6 (Ly5.1)
mice received a myeloablative dose (950 cGy) followed
by infusion of 107 congeneic bone marrow cells
(BMCs) from C57BL/6 (Ly5.2) donors into the tail
veins of recipient mice. Recipients received 60-mg
CDDO-Me or vehicle control daily on days 1-13 after
BMT. Mice were sacrificed on day 14, and spleens and
bone marrow were harvested.RESULTS
CDDO-Me Stimulates GM-CFU Colony Growth
in Vitro
We first studied the effects of CDDO-Me on my-
eloid progenitor differentiation and expansion ex vivo
by culturing naive C57BL/6 bone marrow cells in the
presence of CDDO-Me at varying concentrations.
Colony formation was stimulated by using a subopti-
mal amount of colony-stimulating cytokines. We
chose 300 pg/mL GM-CSF to stimulate myeloid
progenitor differentiation in these assays, as we found
this dose to induce 50% as many colonies as with an
optimal dose of cytokines (10 ng/mL rmGM-CSF,
10 ng/mL rmIL-3; data not shown). These data could
only be reproduced under conditions of suboptimal
cytokines, as higher concentrations of colony-
promoting cytokines most likely masked any direct ef-
fects of CDDO-Me. As expected, given the effects of
CDDO-Me on inhibitingNF-kB, high concentrations
of CDDO-Me above 10 nM significantly decreased
the number of colonies formed in a 7-day GM-CFU
assay (Figure 1). However, in contrast, a low dose of
0.5 nM CDDO-Me significantly stimulated colony
growth ex vivo, suggesting direct myelopoietic effects
of the CDDO-Me on BMCs. The amount of the vehi-
cle present in each dish was kept constant in these stud-
ies because of the potentially toxic effects of the vehicle
necessary to achieve solubility of CDDO-Me: a solu-
tion of 0.9% saline containing 10% DMSO, 10%
Cremophor EL. This vehicle control (VC) was used
as a comparison in all subsequent experiments. Thus,CDDO-Me appears to be able, at low concentrations,
to directly promote myelopoiesis.CDDO-Me Expands Myeloid CD11b1 Gr-11
Cells in the Spleen and Bone Marrow
We next evaluated the ability of CDDO-Me to
stimulate myeloid expansion in vivo in naive mice.
C57BL/6 mice were treated with CDDO-Me or vehi-
cle control (120-mg/dose, twice daily) for 7 days or
G-CSF (2.5 mg/dose, twice daily) for 5 days. Spleens
and femurs were collected, processed, and stained for
flow cytometric analysis of CD11b1 Gr-11 myeloid
cells (Figure 2A-C). Both mouse monocytes and neu-
trophils were phenotyped by CD11b and Gr-1
(Ly6G/C) expression: monocytes exist as CD11b1/
Gr-1hi, Gr-1int, or Gr-1low populations, whereas neu-
trophils are also Gr-1hi [16]. Although these popula-
tions can be further differentiated by flow cytometric
panels to identify the phenotype and maturation state
of each population, we gated total CD11b1 Gr-11
events in the spleen and bone marrow as a broad indi-
cator of myelopoietic activity. In the spleen, CDDO-
Me increased both the percentage and the number of
total myeloid cells (3.18  106 6 1.06  106) 2.5-fold
compared with vehicle control (1.27  106 6 0.415 
106), although not to the extent of G-CSF (1.41 
1076 2.46 106), a positive control formyeloid expan-
sion in the periphery (Figure 2). Similarly, CDDO-Me
expanded CD11b1 Gr-11 myeloid cells in the bone
marrow two-fold, where a much larger population of
myeloid cells exists in naive mice. This myeloid expan-
sion in the bone marrow was similar to the expansion
observed with the administration of G-CSF
(Figure 2). We did not observe a change in either the
Figure 2. CDDO-Me administration causes a myeloid expansion in the spleen and bone marrow. C57BL/6 mice were treated for 7 days with
vehicle control (VC) or CDDO-Me, or 5 days with G-CSF, after which mice were sacrificed, and spleens and bone marrow were harvested.
Single-cell suspensions were stained with anti-CD11b and anti-Gr-1. (A) Representative flow cytometry panels showing percentages of cells in
either organ. (B, C) Total CD11b1Gr-11 cell numbers in the spleen and bone marrow were enumerated. P values were determined by Dunnett’s
multiple comparison test.
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within the spleen or bone marrow. Thus, in vivo treat-
ment of mice with CDDO-Me promoted myeloid cell
expansion to an extent comparable with G-CSF.
CDDO-Me Administration Results in an
Increase in GM-CFU and BFU-E in the Bone
Marrow, Spleen, and Blood
Given the increased total myeloid cells observed in
CDDO-Me-treated mice, we performed GM-CFUand BFU-e colony assays to determine if CDDO-Me
treatment acted on terminal stages of myeloid differ-
entiation or in early hematopoietic development and
what lineages were specifically enhanced. Mice were
treated as before and sacrificed on day 7. Splenocytes
and bone marrow cells were plated for GM-CFU
and BFU-e colony assays to detect myeloid or ery-
throid progenitors, respectively, with optimal concen-
trations of growth-stimulating cytokines (10 ng/mL
rmGM-CSF, 10 ng/mL rmIL-3, and 5 U/mL
VC CDDO-Me G-CSF
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Figure 3. CDDO-Me administration results in a significant increase of GM-CFU and BFU-e in the BM and periphery. Mice were treated with vehicle
control (VC), CDDO-Me, or G-CSF as before. GM-CFU and BFU-e colony assays were performed on bone marrow, spleens, and peripheral blood of
treated animals. The data are representative of three independent experiments with three mice per group per experiment. Statistical differences were
determined by one-way ANOVA with Tukey’s posttest, and a P value\.05 was considered significant.
400 Biol Blood Marrow Transplant 18:396-405, 2012E. Ames et al.erythropoietin). Colonies were allowed to incubate for
7 days before GM-CFU or BFU-e colonies were
counted. CDDO-Me-treated mice displayed an ex-
pansion of both GM-CFU and BFU-e progenitor cells
in the bone marrow, spleen, and blood (Figure 3). As
expected, G-CSF treatment resulted in an increase in
GM-CFU and BFU-e in both the spleen and blood,
but not the bone marrow, consistent with clinical
observations of stem cell mobilization after G-CSF
treatment. The retention of myeloid progenitors in
the bone marrow after CDDO-Me but not G-CSF
treatment implicates a discrete mechanism for
CDDO-Me-induced myelopoiesis. Similarly, high-
proliferative-potential (CFU-HPP) progenitors in
the spleen and bone marrow were enumerated after
CDDO-Me treatment. CDDO-Me treatment in-
creased the number of CFU-HPP significantly in the
spleen and nonsignificantly in the bone marrow
(Figure 4). G-CSF caused a pronounced increase in
splenic CFU-HPP, resulting in colony formation too
numerous to count but showed no effect in the bone
marrow.CDDO-Me Expands HPCs in the Spleen and
Bone Marrow
We next determined whether the increased GM-
CFU and BFU-e colony-forming cells observed in
the spleen and bone marrow after CDDO-Me treat-
ment would correlate with increased numbers of mul-
tipotent HPCs in each organ. HPCs in the spleen and
bone marrow were assessed by staining single-cell sus-
pensions of CDDO-Me or G-CSF-treated mice with
lineage markers, c-kit (stem cell factor receptor),Sca-
1 (stem cell antigen-1), and 7-AAD to exclude dead
cells. We observed an increase in the number of lin2
c-kit1 Sca-11 HPCs in both the bone marrow (3.9-
fold) and spleen (4.5-fold) of CDDO-Me-treated
mice (Figure 5A-C). The increase in HPCs in the
spleen after CDDO-Me treatment was less pro-
nounced than observed with G-CSF treatment (8.9-
fold). Interestingly, treatments with G-CSF or
CDDO-Me equally increased the number of HPCs
in the bone marrow, suggesting that higher numbers
of HPCs in G-CSF-treated mice did not lead to in-
creased GM-CFU or BFU-e as observed in Figure 3.
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Figure 4. CDDO-Me administration results in increased CFU-HPP in the spleen and BM. Mice were treated with vehicle control or CDDO-me (120-
mg/dose two times a day) a day i.p. for 7 days. Bonemarrow and spleenwere collected at day 7, processed into single-cell suspensions and used for colony
assays. Recombinant hG-CSF (2.5-mg/dose two times a day) was used as a control.The number of CFU-HPP colonies were enumerated in both the spleen
(A) and femurs (B). The data are representative of three independent experiments with three mice per group per experiment. Statistical differences
were determined by one-way ANOVA (Tukey) and P value\.05 was considered significant. TNTC 5 too numerous to count.
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can affect early hematopoietic progenitors and HPC
expansion in vivo in a manner distinct from mobiliza-
tion via G-CSF.
CDDO-Me Improves Hematopoietic Recovery
When Administered Before Sublethal Total
Body Irradiation
We next assessed whether CDDO-Me administra-
tion before sublethal total body irradiation (TBI)
would accelerate myeloid recovery. C57BL/6 mice
were myelosuppressed with 500 cGy of TBI after ad-
ministration of CDDO-Me or vehicle control. Mice
received 120-mg CDDO-Me or vehicle control twice
daily on days 27 through 21 before irradiation on
day 0. Mice were sacrificed on day 8 to determine
the extent of hematopoietic recovery. Spleens were
harvested and counted for all treatment groups
(Figure 6). Spleens of mice pretreated with CDDO-
Me were significantly larger than control spleens
(1.82  107 6 0.19 versus 7.37  107 6 2.44; 4.1-
fold) and displayed a significant increase in neutro-
phils, although other cell types were not significantly
increased. Importantly, CDDO-Me pretreatment in-
creased GM-CFU colony numbers 14-fold in the
spleen to levels similar to those seen in naive, unirradi-
ated mice. Interestingly, no effects on peripheral blood
composition recovery were observed suggesting that
CDDO-Me is relatively restricted to early lineage
recovery.
CDDO-Me Administration After Congenic
HSCT Improves Myeloid Recovery
Because of the expansion of myeloid progenitors
seen in naive mice after CDDO-Me administration,
we hypothesized that CDDO-Me could acceleratemy-
eloid recovery after HSCT. C57BL/6 mice were le-
thally irradiated with 950 cGy and intravenously
injected with 107 Ly5.2 congenic bone marrow cells.
We performed a dose titration of CDDO-Me after
HSCT and identified a dose of 60 mg per day as themaximum tolerated dose; the dose used in naive mice
(120 mg twice a day) was lethal in 100% of mice by
day 7 after HSCT primarily because of gut toxicity
(data not shown). Therefore, we administered 60-mg
CDDO-Me or vehicle control daily on days 1–13 after
congenic HSCT. Mice were sacrificed on day 14 after
HSCT and analyzed for myeloid and erythroid pro-
genitors as well as donor (CD45.1) myeloid recovery
(Figure 7). CDDO-Me administration resulted in sig-
nificant increases in BFU-e progenitors as well as
donor CD45.11 CD11b1 Gr-11 cells in the spleen
compared with vehicle control. However, CDDO-
Me did not induce progenitor differentiation or
myeloid expansion in the femur, and CBC were not
significantly different consistent with the early lineage
effects observed.DISCUSSION
We have shown that the synthetic triterpenoid,
CDDO-Me, is a potent inducer of myeloid progenitor
expansion and terminal differentiation both in vitro
and in vivo. Adding CDDO-Me directly to naive
bonemarrow cells in aGM-CFU assay significantly in-
creased colony counts when cultured in suboptimal
colony-stimulating cytokines. Because the number of
myeloid progenitor cells capable of producing GM-
CFU colonies is fixed in these assays, increased colony
counts suggest that CDDO-Me enhances the activity
of GM-CSF to induce terminal differentiation of
these progenitors. However, in vivo treatments with
CDDO-Me not only increased CD11b1/Gr-11 mye-
loid cells but also myeloid progenitor cells. Splenic
CD11b1/Gr-11 cells have been described as
myeloid-derived suppressor cells, which regulate sup-
pressive activity on a broad variety of immune cells.
In this regard, an expansion of CD11b1/Gr-11 cells
would be expected to suppress antitumor activity;
however, Nagaraj et al. [12] recently described that
treatment of myeloid-derived suppressor cells with
CDDO-Me eliminated the suppressive ability of these
Figure 5. CDDO-me administration increases the number of hematopoietic progenitor cells in the bonemarrow and spleen. Mouse bonemarrow and
spleens were collected after the previously described treatment schedule and stained for lineage markers, c-kit, Sca-1, and 7-AAD to exclude dead cells.
7-AAD emits in the same fluorescent channel as the lineage markers used in this study (PE-Cy-5); thus, dead cells were eliminated from gating during
lineage exclusion. (A) Representative flow plots of spleens and bone marrow HPCs are displayed. (B, C) Total bone marrow and spleen hematopoietic
progenitor cells were determined. Statistical differences were determined by one-way ANOVAwith Tukey’s posttest, and a P value\.05 was considered
significant.
402 Biol Blood Marrow Transplant 18:396-405, 2012E. Ames et al.cells. CDDO-Me-treated mice displayed increased
colony counts, indicative of a higher amount ofmyeloid
and erythroid progenitors present in each organ. Inter-
estingly, CDDO-Me showed similar effects in both the
periphery and the bone marrow. Treatment of mice
with G-CSF caused an increase of differentiated
CD11b1/Gr-11 cells in both the spleen and bonemar-
row similar to CDDO-Me. However, G-CSF failed to
induce GM-CFU or BFU-e colony formation in the
bone marrow. The mobilization of hematopoieticstem cells into the peripheral blood by G-CSF has
been well characterized because of its importance in
HSCT [17,18]. G-CSF disturbs interactions between
the chemokine SDF-1 and its receptor, CXCR4, allow-
ing HSCs to escape into the periphery. Similarly,
a CXCR4 agonist (AMD3100, plerixafor) was FDA ap-
proved in 2008 for mobilizing peripheral blood in con-
junction with G-CSF in patients undergoing
autologous HSCTs for multiple myeloma and non-
Hodgkin lymphoma [19]. G-CSF also increased
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Figure 6. CDDO-Me is radioprotective when administered before sublethal TBI. Mice were treated with CDDO-Me or vehicle control on days 27
through 21 before sublethal TBI. Mice were harvested on day 8 after irradiaiton. (A) Total nucleated cell counts in the spleen were quantified.
(B) Leukocyte cell types in the spleen were quantified by flow cytometry for vehicle control (white bars) and CDDO-Me (black bars) treated mice.
(C) The total number of GM-CFU cells per spleen were quantified. Statistical differences were determined by one-way ANOVA with Tukey’s posttest,
and a P value\.05 was considered significant.
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interesting observation, given the use of G-CSF as an
HSC mobilizer. Although bone marrow HSCs are in-
frequently examined in studies concerning G-CSF in
naive mice, this observation has been previously shown
either alone or in combination with cyclophosphamide
[20,21]. However, the increased HPCs in the bone
marrow of G-CSF-treated mice failed to induce
GM-CFU colony formation. This observation may
give insight into the differential mobilization of various
subsets in the bonemarrow.Whereas LT- or ST-HSC
may require a higher threshold to become mobilized,
more differentiated myeloid cells may have a lower
threshold because of increased responsiveness to
G-CSF. Kim et al. [17] demonstrated that CXCR4
expression was highly responsive to incubation with
G-CSF in human CD331 bone marrow cells, whereas
CD332 cells showed no change in CXCR4 expression.
Although G-CSF treatment may increase HSCs in the
bone marrow with some of these cells becoming mobi-
lized and some remaining, as these cells differentiate
toward the myeloid lineage, they may mobilize more
rapidly because of decreased CXCR4 expression.
This differential mobilization may account for the
lack of any differences in GM-CFU or BFU-e colonies
between mice treated with G-CSF or vehicle control.
In contrast, CDDO-Me appears to act not as a bone
marrow mobilizer but rather as a broad stimulator of
stem cell expansion and differentiation down the mye-
loid lineage. CDDO-Me induced a robust expansion of
progenitor cells on three levels:HPCs,CFU-HPP, and
GM-CFU/BFU-e. Interestingly, the magnitude of theeffect induced by CDDO-Me seemed to decrease with
increasing ‘‘primitiveness’’ of the precursor cells exam-
ined.
We were unable to determine the mechanism of
action of CDDO-Me-induced myelopoiesis. The
sera of treated mice were tested for colony-
stimulating cytokines by ELISA as well as mRNA
transcripts of cytokines and chemokines and chemo-
kine receptors associated with hematopoieisis and
mobilization on spleen and bone marrow samples
but were inconclusive in CDDO-Me-treated ani-
mals. Because of the discrete mechanism of action
of CDDO-Me versus G-CSF, it is unlikely that
CDDO-Me induces a similar profile of surface recep-
tor modulation and cytokine secretion as with G-
CSF. However, the ability of CDDO-Me to induce
differentiation of na€ıve bone marrow cells into
GM-CFU colonies suggests a direct cellular mecha-
nism of action. Mice lacking IkBa have been reported
to show sharply increased CFU-GEMM, suggesting
a role for NF-kB in myelopoiesis [22]. Given that
CDDO-Me blocks IlBa kinase-b (IKK-b) and thus
prevents IkBa from becoming phosphorylated, the
mechanism of action of CDDO-Me may lie in the
NK-kB pathway.
The most important application for CDDO-Me
may be in the context of HSCT. When administered
before sublethal TBI, CDDO-Me improves hemato-
poietic recovery, most significantly in neutrophils.
This finding may be because of either general antioxi-
dant and anti-inflammatory properties of CDDO-Me,
which have been shown to be radioprotective [23] or
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Figure 7. CDDO-Me administration after HSCTaccelerates myeloid recovery. C57BL/6 (CD45.2) mice underwent a congenic BMTwith 107 BMCs
from C57BL/6 Ly5.2 (CD45.1) donors. Mice received 60-mg CDDO-Me daily on days 1 through 13 after BMT. Mouse spleens and femurs were collected
on day 14 and were assessed for GM-CFU and BFU-e activity. Donor myeloid cells (CD45.11/CD11b1/Gr-11) were also assessed by flow cytometry.
Statistical differences were determined by Student’s t-test, and a P value\.05 was considered significant.
404 Biol Blood Marrow Transplant 18:396-405, 2012E. Ames et al.the increase in hematopoietic progenitor cells. Primi-
tive hematopoietic cells display decreased sensitivity
to irradiation-induced damage, most likely because
of their quiescent state [24]. By increasing the number
of these precursor cells, CDDO-Me helps to maintain
hematopoietic function post-TBI whenmore differen-
tiated cells are ablated. CDDO-Me administration
posttransplantation also increased GM-CFU and
BFU-e recovery. Importantly, CDDO-Me accelerated
the recovery of neutrophils and all CD11b1/Gr-11
cells, which are clinical indicators of hematopoietic re-
covery posttransplantation. Furthermore, we have pre-
viously shown that CDDO-Me and its parent
compound, CDDO, delay GVHD while still main-
taining graft-versus-leukemia effects [13,25] in addi-
tion to direct antitumor effects of CDDO-Me. In
this previous report, we also examined effects on he-
matopoietic recovery in an allogeneic model and ob-
served increased engraftment and HSCT recovery
data in that study but could not determine if theeffects were direct or affecting host resistance mecha-
nisms. The current study demonstrates that direct ef-
fects can indeed occur. Clinically, CDDO-Me may
potentially be used to supplement G-CSF both in
the setting of HSC mobilization and HSCT recovery.
Given the distinct mechanisms of action and sites of
myeloid expansion seen in CDDO-Me and G-CSF,
these agents may show synergistic effects when given
in concert. Combined, these data suggest multiple
advantageous effects of CDDO-Me when adminis-
tered before or after allogeneic or autologous
transplantations.ACKNOWLEDGMENTS
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